LEGACY: Phase 2a Trial to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamic Effects of the Anti-EL (Endothelial Lipase) Antibody MEDI5884 in Patients With Stable Coronary Artery Disease.
Christian T RuffMichael J KorenJoseph GrimsbyAnton I RosenbaumXiao TuSotirios K KarathanasisJudith FalloonJudith HsiaYe GuanJames P ConwayLan-Feng TsaiB Timothy HummerBoaz HirshbergJulia F KuderSabina A MurphyRichard T GeorgeMarc S SabatinePublished in: Arteriosclerosis, thrombosis, and vascular biology (2021)
Inhibition of EL by MEDI5884 increases the quantity and quality of functional HDL in patients with stable coronary artery disease on high-intensity statin therapy without an adverse safety signal at the likely dose to be used. These data support further clinical investigation. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT03351738.
Keyphrases
- coronary artery disease
- high intensity
- percutaneous coronary intervention
- cardiovascular events
- resistance training
- coronary artery bypass grafting
- study protocol
- clinical trial
- cardiovascular disease
- phase iii
- phase ii
- emergency department
- type diabetes
- aortic stenosis
- stem cells
- data analysis
- mesenchymal stem cells
- heart failure
- acute coronary syndrome
- bone marrow
- cell therapy
- quality improvement
- double blind